Loading clinical trials...
Loading clinical trials...
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Conditions
Interventions
imatinib mesylate
Locations
21
United States
University of California San Diego - Moores Cancer Center Moores UCSD Cancer Center (31)
La Jolla, California, United States
University of Colorado University of Colorado
Aurora, Colorado, United States
Washington Hospital Center Department of Medical Oncology
Washington D.C., District of Columbia, United States
University Cancer & Blood Center, LLC
Athens, Georgia, United States
Longstreet Cancer Center
Gainesville, Georgia, United States
Kootenai Medical Center Kootenai Cancer Cancer
Coeur d'Alene, Idaho, United States
Start Date
July 22, 2009
Primary Completion Date
December 20, 2016
Completion Date
December 20, 2016
Last Updated
March 14, 2018
NCT03594422
NCT06655246
NCT07072143
NCT05009927
NCT00780494
NCT02574663
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions